713 related articles for article (PubMed ID: 29143875)
1. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT in pancreatic adenocarcinoma: A role at initial imaging staging?
Wartski M; Sauvanet A
Diagn Interv Imaging; 2019 Dec; 100(12):735-741. PubMed ID: 31402332
[TBL] [Abstract][Full Text] [Related]
3. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
4. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
5. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
[TBL] [Abstract][Full Text] [Related]
7. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.
Wang ZJ; Behr S; Consunji MV; Yeh BM; Ohliger MA; Gao K; Ko AH; Cinar P; Tempero MA; Collisson EA
AJR Am J Roentgenol; 2018 Nov; 211(5):1010-1019. PubMed ID: 30063366
[TBL] [Abstract][Full Text] [Related]
8. Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET.
Toesca DAS; Pollom EL; Poullos PD; Flynt L; Cui Y; Quon A; von Eyben R; Koong AC; Chang DT
Pract Radiat Oncol; 2017; 7(2):120-125. PubMed ID: 28274396
[TBL] [Abstract][Full Text] [Related]
9. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study.
Furtado FS; Ferrone CR; Lee SI; Vangel M; Rosman DA; Weekes C; Qadan M; Fernandez-Del Castillo C; Ryan DP; Blaszkowsky LS; Hong TS; Clark JW; Striar R; Groshar D; Cañamaque LG; Umutlu L; Catalano OA
Mol Imaging Biol; 2021 Jun; 23(3):456-466. PubMed ID: 33415677
[TBL] [Abstract][Full Text] [Related]
10.
Palmieri LJ; Coriat R
Diagn Interv Imaging; 2019 Dec; 100(12):731-733. PubMed ID: 31780041
[No Abstract] [Full Text] [Related]
11. Usefulness of
Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
[TBL] [Abstract][Full Text] [Related]
12. Prospective comparison of (4S)-4-(3-
Cheng MF; Huang YY; Ho BY; Kuo TC; Hsin LW; Shiue CY; Kuo HC; Jeng YM; Yen RF; Tien YW
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):810-820. PubMed ID: 30635754
[TBL] [Abstract][Full Text] [Related]
13. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
[No Abstract] [Full Text] [Related]
14. What Can We Learn About Pancreatic Adenocarcinoma from Imaging?
Rosenthal M; Schawkat K; Muftah M; Jajoo K
Hematol Oncol Clin North Am; 2022 Oct; 36(5):911-928. PubMed ID: 36265990
[TBL] [Abstract][Full Text] [Related]
15. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.
Ghaneh P; Hanson R; Titman A; Lancaster G; Plumpton C; Lloyd-Williams H; Yeo ST; Edwards RT; Johnson C; Abu Hilal M; Higginson AP; Armstrong T; Smith A; Scarsbrook A; McKay C; Carter R; Sutcliffe RP; Bramhall S; Kocher HM; Cunningham D; Pereira SP; Davidson B; Chang D; Khan S; Zealley I; Sarker D; Al Sarireh B; Charnley R; Lobo D; Nicolson M; Halloran C; Raraty M; Sutton R; Vinjamuri S; Evans J; Campbell F; Deeks J; Sanghera B; Wong WL; Neoptolemos JP
Health Technol Assess; 2018 Feb; 22(7):1-114. PubMed ID: 29402376
[TBL] [Abstract][Full Text] [Related]
16. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
[TBL] [Abstract][Full Text] [Related]
17. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
18. Imaging for pancreatic ductal adenocarcinoma.
Horvat N; Ryan DE; LaGratta MD; Shah PM; Do RK
Chin Clin Oncol; 2017 Dec; 6(6):62. PubMed ID: 29307202
[TBL] [Abstract][Full Text] [Related]
19. Impact of
Röhrich M; Naumann P; Giesel FL; Choyke PL; Staudinger F; Wefers A; Liew DP; Kratochwil C; Rathke H; Liermann J; Herfarth K; Jäger D; Debus J; Haberkorn U; Lang M; Koerber SA
J Nucl Med; 2021 Jun; 62(6):779-786. PubMed ID: 33097632
[TBL] [Abstract][Full Text] [Related]
20. PET/MRI and PET/CT hybrid imaging of rectal cancer - description and initial observations from the RECTOPET (REctal Cancer trial on PET/MRI/CT) study.
Rutegård MK; Båtsman M; Axelsson J; Brynolfsson P; Brännström F; Rutegård J; Ljuslinder I; Blomqvist L; Palmqvist R; Rutegård M; Riklund K
Cancer Imaging; 2019 Jul; 19(1):52. PubMed ID: 31337428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
